Epocrates (Nasdaq: EPOC) is expected to report Q4 earnings around Feb. 28. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Epocrates's revenues will decrease -0.5% and EPS will decrease -20.0%.

The average estimate for revenue is $29.6 million. On the bottom line, the average EPS estimate is $0.04.

Revenue details
 Last quarter, Epocrates chalked up revenue of $26.0 million. GAAP reported sales were 2.1% lower than the prior-year quarter's $26.6 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, non-GAAP EPS came in at $0.02. GAAP EPS were -$0.02 for Q3 compared to $0.03 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was 58.5%, 280 basis points worse than the prior-year quarter. Operating margin was -4.3%, 690 basis points worse than the prior-year quarter. Net margin was -2.3%, 490 basis points worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $109.9 million. The average EPS estimate is $0.19.

Investor sentiment
 The stock has a three-star rating (out of five) at Motley Fool CAPS, with 36 members out of 39 rating the stock outperform, and three members rating it underperform. Among nine CAPS All-Star picks (recommendations by the highest-ranked CAPS members), nine give Epocrates a green thumbs-up, and give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Epocrates is hold, with an average price target of $11.00.

Is Epocrates the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.